Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.51 USD
+0.01 (0.40%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $2.52 +0.01 (0.40%) 7:04 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Allogene Therapeutics, Inc. [ALLO]
Reports for Purchase
Showing records 161 - 180 ( 215 total )
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Full Measure to Address Host Rejection
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR II Posters Demonstrate Efforts to Advance Allogeneic CAR-T Platform
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Patient Selection for Retreatment; Target Lowered to $49 to Reflect Secondary Offering
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
So Far So Good, Nothing Untoward With High Dose Anti- CD52 and CR''s Appear Durable
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early but Clear Signs of a Significant Lymphoma Therapy
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Reminder to Register for Our Pre-ASCO Webinar
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early, but a Buy Now with PT Raised to $60/share.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Promising Early Activity; ALLO-501/A + ALLO-647 Might Be on to Something; Raising Target to $42
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D